Form 4: Hologic CEO MacMillan Reports Stock Transactions

Hologic's Chairman, President, and CEO, Stephen P. MacMillan, reported recent transactions involving the company's common stock, including tax-related dispositions and the grant of restricted stock units.

Summary

• Stephen P. MacMillan, Chairman, President, and CEO of Hologic Inc. (HOLX), reported changes in his beneficial ownership of common stock.
• On November 7, 2025, 50,405 shares of common stock were disposed of at a price of $74.1 per share to cover tax obligations related to the settlement of performance stock units/restricted stock units.
• On November 10, 2025, 169,582 restricted stock units (RSUs) were acquired. These RSUs will vest in equal installments on each of the first three anniversaries of the grant date.
• On November 11, 2025, an additional 6,679 shares of common stock were disposed of at a price of $74.6 per share for tax obligations.
• Following these transactions, Mr. MacMillan directly beneficially owns 1,430,711 shares of common stock, which includes 1,079,673 restricted stock units/performance stock units whose settlement has been deferred.
• Mr. MacMillan also indirectly beneficially owns 1,146,829 shares through the MacMillan Family Trust.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions, including the grant of restricted stock units which aligns management's interests with long-term shareholder value, balanced by standard tax-related share dispositions.

Positives

• The grant of 169,582 restricted stock units (RSUs) to the CEO aligns management's long-term interests with shareholder value, as these units vest over three years.

Negatives

• Dispositions of 50,405 shares and 6,679 shares were made to satisfy tax obligations, which is a routine event for equity compensation but reduces direct ownership.

Future Outlook

The 169,582 restricted stock units granted on November 10, 2025, are scheduled to vest in equal installments on each of the first three anniversaries of the grant date, indicating future share issuances tied to continued service.

Industry Context

This Form 4 filing details routine insider transactions for a public company executive. Such filings are standard disclosures required by the SEC to provide transparency regarding changes in beneficial ownership by company insiders, which can offer insights into management's confidence and compensation structure within the broader industry context.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CEO aligns his incentives with long-term shareholder value creation. The tax-related dispositions are routine and have minimal impact.
• Employees: The filing reflects standard executive compensation practices, which may influence broader compensation strategies within the company.

Next Steps

• The granted restricted stock units will vest in equal installments on the first three anniversaries of November 10, 2025.

Key Dates

Recommendation

This Form 4 details routine insider transactions, specifically the grant of restricted stock units as part of compensation and subsequent share dispositions for tax obligations. These transactions are typical for executives and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment thesis. Investors should continue to hold based on broader company fundamentals rather than these standard insider filings.

Keywords

Hologic, HOLX, Form 4, Insider Transaction, Stephen MacMillan, CEO, Restricted Stock Units, RSU, Performance Stock Units, PSU, Beneficial Ownership